Apogee Therapeutics Inc. (APGE)
NASDAQ: APGE
· Real-Time Price · USD
37.36
-0.76 (-1.99%)
At close: Aug 15, 2025, 3:59 PM
36.48
-2.36%
After-hours: Aug 15, 2025, 07:58 PM EDT
Apogee Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 |
Revenue | 130K | 130K | 130K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 655K | 291K | 113K | 113K | 65K | 29K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | -590K | -226K | -48K | -113K | -65K | -29K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -270.83M | -241.78M | -216.87M | -178.14M | -143.76M | -118.53M | -93M | -69.95M | -56.15M | -39.08M | -30.73M | -16.63M | -6.12M | -4.3M |
Interest Income | 33.33M | 36.49M | 34.74M | 31.48M | 25.28M | 14.97M | 9.02M | 3.69M | 225K | 225K | 92K | n/a | n/a | n/a |
Pretax Income | -171.55M | -205.29M | -182.13M | -146.66M | -118.48M | -103.55M | -83.98M | -66.26M | -65.07M | -48.01M | -39.78M | -25.78M | -6.12M | -4.3M |
Net Income | -171.57M | -205.39M | -182.15M | -146.66M | -118.48M | -103.55M | -83.98M | -66.26M | -65.07M | -48.01M | -39.78M | -25.78M | -6.12M | -4.3M |
Selling & General & Admin | 62.8M | 56.25M | 48.98M | 41.52M | 35.79M | 29.81M | 24.58M | 18.27M | 11.65M | 7.08M | 2.94M | 1.05M | 428K | 60K |
Research & Development | 208.03M | 185.54M | 167.87M | 136.59M | 107.94M | 88.69M | 68.42M | 51.68M | 44.49M | 32M | 27.79M | 15.58M | 5.69M | 4.25M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 270.83M | 241.78M | 216.84M | 178.12M | 143.73M | 118.5M | 93M | 69.95M | 56.15M | 39.08M | 30.73M | 16.63M | 6.12M | 4.3M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 9.15M | 9.15M | 9.15M | 9.15M | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | -29K | -29K | -29K | -29K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 270.83M | 241.78M | 216.87M | 178.14M | 143.76M | 118.53M | 93M | 69.95M | 56.15M | 39.08M | 30.73M | 16.63M | 6.12M | 4.3M |
Income Tax Expense | -137K | -65K | 3.72K | -51.43K | -51.43K | -70.32K | -68.7K | 5.58K | -4.93K | 13.96K | 26.61K | -10.51K | n/a | n/a |
Shares Outstanding (Basic) | 58.43M | 58.2M | 55.19M | 56.8M | 56.52M | 50.19M | 50.66M | 50.67M | 50.67M | 50.67M | 50.67M | 50.67M | 50.67M | 50.67M |
Shares Outstanding (Diluted) | 58.43M | 58.2M | 55.19M | 56.8M | 56.52M | 50.19M | 50.66M | 50.67M | 50.67M | 50.67M | 50.67M | 50.67M | 50.67M | 50.67M |
EPS (Basic) | -4.16 | -3.63 | -3.32 | -2.73 | -2.28 | -2.05 | -1.66 | -1.31 | -1.29 | -0.96 | -0.79 | -0.51 | -0.12 | -0.09 |
EPS (Diluted) | -4.16 | -3.63 | -3.32 | -2.73 | -2.28 | -2.05 | -1.66 | -1.31 | -1.29 | -0.96 | -0.79 | -0.51 | -0.12 | -0.09 |
EBITDA | -270.7M | -241.63M | -216.68M | -172.61M | -134.81M | -109.61M | -71.46M | -39.73M | -18.89M | n/a | n/a | n/a | n/a | n/a |
EBIT | -255.85M | -233.94M | -216.87M | -172.72M | -134.88M | -109.64M | -84.12M | -66.39M | -56.06M | -38.99M | -30.64M | -16.63M | -6.12M | -4.3M |
Depreciation & Amortization | 331K | 367K | 189K | 113K | 65K | 18.91M | 31.54M | 48.44M | 58.94M | 41.87M | 33.52M | 16.63M | 6.12M | 4.3M |